SANA (Sana Biotechnology) Market Value to Book Value Ratio

Official company branding of Sana Biotechnology (SANA)

The development of Sana Biotechnology (SANA) relies on scientific research, rendering it independent of economic cycles, with the current indicator standing at 4.71. The linear price action on this chart complements data regarding laboratory modernization and the implementation of automation to expand capacity. The business advantage lies in the creation of modified cells that are not recognized by the immune system, eliminating the risk of rejection during treatment.

Sana Corp (SANA): Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for Sana Biotechnology Inc (SANA)

- price and consensus price forecast:
Stock Price Sana Biotechnology|SANA - Analyst Consensus Forecast
- market capitalization data:
Market Value Sana Bio|SANA - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Sana Biotechnology|SANA - Accounting Capitalization|Market Capitalization to Book Value Ratio sana.com|SANA - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Sana Biotechnology|SANA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Sana Bio|SANA - Company Debts|Debt to Book Capitalization Ratio Sana Bio|SANA - Long-Term Debt|Company Short-Term Debts Sana Biotechnology
Fundamental valuation:Sana Biotechnology
Brand item of Sana Bio

This ratio measures the market value premium over net asset value, allowing investors to assess the extent to which the share price is inflated relative to book equity. By analyzing the degree to which market capitalization exceeds book value, one can determine how much the market currently prices in the future success of Sana Biotechnology (SANA) R&D developments in cell modification for cancer and diabetes therapies.

Competitor analysis

LEGN: Market Capitalization to Book Value Ratio|AUTL (autolus.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio ALLO (Allogene)|Market-to-Book Ratio RNAC|Market Value to Book Value Ratio Cellectis S.A. CLLS|Capitalization to Book Value Ratio Caribou Biosciences, Inc (CRBU)|Instil Bio, Inc. - Market Capitalization to Book Value Ratio|Genenta Science SpA - Market Cap to Net Assets Ratio|IPSC (Century Therapeutics Inc) - Market Value to Book Value Ratio|JSPR: Market-to-Book Ratio|sentibio.com (SNTI) - Market Value to Book Value Ratio|ADAP (Adaptimmune Therapeutics) - Market Value to Book Value Ratio|Market Value to Book Value Ratio CERO (CERo Therapeutics Holdings, Inc.)|Market-to-Book Ratio Alaunos|ACHL: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio CARGO Therapeutics Inc. CRGX|PSTX: Market Cap to Net Assets Ratio|TSVT - Market-to-Book Ratio|Market Cap to Net Assets Ratio Gracell Biotechnologies (GRCL)